These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Dvorak HF; Nagy JA; Dvorak AM Cancer Cells; 1991 Mar; 3(3):77-85. PubMed ID: 1711364 [TBL] [Abstract][Full Text] [Related]
24. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology]. Chiron MF Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366 [TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody therapy for cancer. von Mehren M; Adams GP; Weiner LM Annu Rev Med; 2003; 54():343-69. PubMed ID: 12525678 [TBL] [Abstract][Full Text] [Related]
26. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers. Scheinberg DA Curr Opin Immunol; 1991 Oct; 3(5):679-84. PubMed ID: 1661602 [TBL] [Abstract][Full Text] [Related]
27. Current status of antitumor therapy with monoclonal antibodies. Scheinberg DA; Houghton AN Oncology (Williston Park); 1987 May; 1(3):31-40. PubMed ID: 3079479 [TBL] [Abstract][Full Text] [Related]
29. Biologic agents in the management of Hodgkin lymphoma. Rashidi A; Bartlett NL J Natl Compr Canc Netw; 2015 May; 13(5):587-96. PubMed ID: 25964642 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754 [TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Milenic DE Curr Pharm Des; 2002; 8(19):1749-64. PubMed ID: 12171546 [TBL] [Abstract][Full Text] [Related]
33. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Strome SE; Sausville EA; Mann D Oncologist; 2007 Sep; 12(9):1084-95. PubMed ID: 17914078 [TBL] [Abstract][Full Text] [Related]
35. Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304 [TBL] [Abstract][Full Text] [Related]
36. [Cancer therapy by using bispecific antibody]. Azuma A; Niitani H; Okumura K Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618 [TBL] [Abstract][Full Text] [Related]
37. Future approaches for treating hematologic disease. Reff M; Braslawsky G; Hanna N Curr Pharm Biotechnol; 2001 Dec; 2(4):369-82. PubMed ID: 11762418 [TBL] [Abstract][Full Text] [Related]
38. Targeted delivery of biologic and other antineoplastic agents. Rowlinson-Busza G; Epenetos AA Curr Opin Oncol; 1992 Dec; 4(6):1142-8. PubMed ID: 1457528 [TBL] [Abstract][Full Text] [Related]
39. [Antibodies as specific tumor therapy agents. Wishful thinking or reality?]. Gramatzki M; Valerius T Internist (Berl); 1997 Nov; 38(11):1055-62. PubMed ID: 9453954 [No Abstract] [Full Text] [Related]
40. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Epstein AL; Khawli LA; Hornick JL; Taylor CR Cancer Res; 1995 Jun; 55(12):2673-80. PubMed ID: 7780984 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]